Casi pharmaceuticals announces fda clearance of ind application for cid-103 in renal allograft antibody-mediated rejection (amr)

Cid-103 is a potential best-in-class, anti-cd38 monoclonal antibody; binds to unique cd38 epitope phase 1 study in adults with active and chronic active renal allograft amr planned to initiate amr is a leading cause of kidney transplant loss, leading to dialysis and/or repeat renal transplant san francisco, ca / access newswire / august 4, 2025 / casi pharmaceuticals, inc. (nasdaq:casi), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced fda clearance of an ind application for cid-103, an anti-cd38 monoclonal antibody in adults with active and chronic active renal allograft antibody mediated rejection (amr). the phase 1 clinical trial is a dose-ranging and safety study evaluating the tolerability and efficacy of cid-103 in patients with amr.
AMR Ratings Summary
AMR Quant Ranking